Heart failure, particularly end-stage biventricular heart failure, is one of the leading causes of death globally. With heart transplants being the only treatment option, the shortage of available donor hearts presents a significant challenge.
Annually, only about 4,000 donor hearts are available, leaving many patients without viable alternatives.
This shortage has spurred the development of innovative solutions, including the Total Artificial Heart (TAH), a groundbreaking smart technology that could transform the treatment of heart failure.
The concept of the TAH was conceived by Daniel Timms, who began working on it as part of his PhD project at Queensland University of Technology in 2008. Raised in Brisbane, Daniel developed an early interest in mechanics, learning from his father, a plumber. However, it was the loss of his father to heart failure at the age of 55 that drove him to focus on finding a solution for heart disease.
Daniel’s vision was to create a long-term therapy for patients with severe biventricular heart failure, a condition affecting both the left and right chambers of the heart. Unlike traditional heart devices, the TAH uses advanced technologies like magnetic levitation and artificial intelligence (AI) to simulate the natural blood flow of a healthy heart.
This innovative approach not only offers a potential alternative to heart transplants but also aims to enhance the quality of life for patients in need of a heart replacement.
By 2018, after successful prototyping and promising test results, Daniel’s company, focused on developing the TAH, sought funding to continue its progress. Developing a medical device of this scale is both high-risk and time-consuming, making it challenging for companies to attract investment, especially during the early stages when a device is still undergoing scientific and technical development.
Despite these challenges, the company secured crucial support through a government-backed venture capital initiative. The Australian government’s Biomedical Translation Fund (BTF) played a pivotal role in supporting the TAH’s development.
Through this program, which co-invests with private venture capital firms, the company partnered with a leading Australian firm. This partnership provided essential financial backing and expertise in research commercialization and navigating international markets.
Thanks to this collaboration, the company successfully advanced through the scientific, regulatory, and technical stages required to bring the device to clinical use. Dr. Paul Kelly, a founding partner of the venture capital firm, explains that the journey from discovery to commercialization can take over 15 years. However, the rewards of medical innovation are immense, offering the potential to significantly impact healthcare systems and improve the lives of patients in need.
Related topics: